
The fund's core mission is to achieve substantial growth in capital over the long term. Income generation, while also pursued, is a secondary objective.
Is TCHP's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

Cwm LLC lessened its position in shares of T. Rowe Price Blue Chip Growth ETF (NYSEARCA:TCHP) by 49.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,658 shares of the company's stock after selling 48,761 shares

Armstrong Fleming and Moore Inc increased its holdings in T. Rowe Price Blue Chip Growth ETF (NYSEARCA:TCHP) by 6.6% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 506,688 shares of the company's stock after buying an additional 31,162

Financial advisors are turning to active ETFs as a solution to navigating concentrated markets. Recent survey data reveals that fundamental research and strong performance top their priority lists.

Active ETFs have continued their ascent to start 2026. The category, which has seen accelerated launches and flows in recent years, surpassed a major milestone in January.

The T. Rowe Price Blue Chip Growth ETF remains a Hold due to persistent underperformance versus the S&P 500 and elevated fees. TCHP's concentrated tech exposure initially drove outperformance, but recent returns have mirrored SPY, eroding its active management thesis. Portfolio overweighting in NVDA, MSFT, AAPL, and GOOG (~43%) has not offset underweights in outperforming sectors like Healthcare and Industrials.